Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02031640 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
A Phase 3 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,113
- Enrollment target
- 20
- Study locations
NCT02031640: Completed Phase 3 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT02031640 is a Phase 3 study of Asthma that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 1,113 participants, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02031640, a Phase 3 study of Asthma, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,113 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.
Primary Outcome
Trough morning FEV1 measurements were taken pre-dose and pre-rescue bronchodilator treatment for asthma. The baseline pulmonary function measurement was defined as the measurement obtained at randomization visit (Day 1). Pulmonary function measurements (including FEV1) were obtained electronically by spirometry. All pulmonary function test data were submitted to a central reading center for evaluation. The highest FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 5 attempts) wa
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Albuterol/salbutamol
- DRUG Beclomethasone dipropionate
Study Locations (20)
California
- Teva Investigational Site 10851 - Costa Mesa
- Teva Investigational Site 10849 - Huntington Beach
- Teva Investigational Site 10872 - Huntington Beach
- Teva Investigational Site 10833 - Long Beach
- Teva Investigational Site 10861 - Los Angeles
- Teva Investigational Site 10798 - Mission Viejo
- Teva Investigational Site 10806 - Orange
- Teva Investigational Site 10828 - Orange
- Teva Investigational Site 10860 - Paramount
- Teva Investigational Site 10813 - Rancho Mirage
- Teva Investigational Site 10843 - Riverside
- Teva Investigational Site 10857 - Rolling Hills Estates
- Teva Investigational Site 10847 - San Diego
- Teva Investigational Site 10871 - San Diego
- Teva Investigational Site 10876 - San Jose
- Teva Investigational Site 12270 - Walnut Creek
Colorado
- Teva Investigational Site 12266 - Centennial
- Teva Investigational Site 10838 - Colorado Springs
- Teva Investigational Site 10844 - Denver
- Teva Investigational Site 10799 - Wheat Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,113 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
What the finished NCT02031640 record still lists
NCT02031640 is an interventional study that assigns participants to a tested intervention. Its 1,113 participants enrollment target places it among the larger protocols in the corpus, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02031640 names 20 study sites across 2 states, led by California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02031640 about?
NCT02031640 is a clinical study titled "A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma". This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.
What is the current status of trial NCT02031640?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,113 participants. The study started on 2013-12. Estimated completion is 2014-12.
What conditions does trial NCT02031640 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02031640?
The interventions under investigation include: Placebo (DRUG), Albuterol/salbutamol (DRUG), Beclomethasone dipropionate (DRUG).
Who is sponsoring clinical trial NCT02031640?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02031640 being conducted?
This trial has 20 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02031640's enrollment target sits among peer trials
1,113 34th of 374 higher than 341 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia